Exact Sciences expects to report 4Q revenue increase of nearly 150%, but shares drop

Exact Sciences Corp., the Madison developer and marketer of the Cologuard colorectal cancer test, said Sunday that it expects to report a 148 percent increase in revenue for the fourth quarter.   Exact Sciences (Nasdaq: EXAS) said it completed 176,000 noninvasive DNA-based Cologuard tests in the fourth quarter, a 115 percent increase from the same period a year ago and within the firm’s guidance of 173,000 to 177,000 tests for the quarter. The company will finish 2017 with a total of about 571,000…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news